The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

According to research presented at the EAHAD 2024 Annual Congress, a new classification system enhances diagnosis and ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

A Lincoln nurse who specialises in looking after patients with blood disorders has been named Nurse of the Year. Alison ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

According to research presented at the EAHAD 2024 Annual Congress, spinal stenosis is emerging as a complication for aging hemophilia patients.

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...